Significant correlations were found between serum urea, serum creatinine and metoclopramide clearance. 5 The metoclopramide regimens were well tolerated and, with the exception of two patients, were completely effective in the prevention of nausea and vomiting. 6 To achieve and maintain target serum metoclopramide concentrations of 1 ,ug/ml, we now administer a loading infusion of 3.61 mg/kg over 30 min followed by a maintenance infusion of 0.36 mg kg-1 h-1 for 10 h. Cyclophosphamide is normally administered concurrently with the second infusion. 7 For patients with evidence of mild renal impairment, the maintenance infusion rate of metoclopramide hydrochloride should be adjusted according to the predicted individual clearance value; CL (1 h-1 kg-') = 0.57 -[0.036 x urea (mmol/1)].
Introduction
Metoclopramide (4 amino-S chloro-N(2 diethylPrevious pharmacokinetic studies in young aminoethyl)-2 methoxybenzamide) is an anti-healthy male volunteers indicate that metoemetic agent whose effect is thought to be exerted clopramide disposition can be described by an through activity at both peripheral (gastro-open two compartment pharmacokinetic model intestinal) and central (chemoreceptor trigger (Bateman etal., 1978) . Rapid absorption usually zone) sites. The pharmacological actions of occurs after oral administration but the drug metoclopramide include dopamine receptor undergoes significant first-pass metabolism and blockade and stimulation of acetylcholine release its bioavailability is subject to considerable inter- (Pinder et al., 1976; Hay et al., 1977) .
individual variability (Bateman et al., 1980 (Vs, , (Bateman, 1983) ) which is characteristic of a weakly protein bound, lipid soluble compound. Hepatic metabolism is the major component of metoclopramide elimination with clearance approximating to liver blood flow (Bateman et al., 1978; Ross-Lee et al., 1981) . Three metabolites have been identified in man; the most predominant is the N-4 sulphate derivative and over 40% of an oral dose may be excreted in this form. Renal excretion of unchanged metoclopramide is responsible for the elimination of approximately 20% of an intravenous dose (Bateman et al., 1980) . Dose dependent disposition has been identified (Graffner et al., 1979) .
Conventional doses of metoclopramide (0.5 mg kg~' day-1) have failed to prevent cytotoxic induced nausea and vomiting. However, Gralla et al. (1981) 2, 3, 4, 6, 10, 12, 15, 20, 30,45,60and90minand2,3,4,6,8, 12,24, 32 and 48 h after bolus administration.
Sample collection
Venous blood samples (5 ml in glass tubes without anticoagulant) were withdrawn through a 'Venflon' indwelling cannula inserted into a contralateral forearm vein. Serum samples were ;.iO subsequently stored at -20°C until required for analysis.
Drug analysis
Serum concentrations of metoclopramide were determined by high performance liquid chromatography (Bryson et al., 1984) .
Data analysis
Unless otherwise specified, the pharmacokinetic symbols used in this paper are those recommended by Rowland & Tucker (1980) . Non linear least squares regression analysis, with constant weighting, was employed for the data analysis. Following the intravenous bolus administration of metoclopramide, all concentration/time data were fitted to a one compartment pharmacokinetic model using the equation C= Coe = and a two compartment model using the equation C = Ae-xt + Be-J where X1 and X, are the first order rate constants of distribution and elimination respectively.
Following the intravenous infusion regimens of metoclopramide, the concentration-time data were fitted to a one compartment model using the equation To show which pharmacokinetic model best fitted the data, the F ratio test was used (Neter & Wasserman, 1974) . To identify the clinical features which were important determinants of metoclopramide clearance, the following factors were assessed for correlation using stepwise multiple linear regression (Neter & Wasserman, 1974) Figures 1 and 2 . These follow intravenous infusion according to protocols A and B respectively in the pilot study. The data were adequately described by a one compartment model and no significant improvement in the fit could be detected by using the two-compartment model. Time (h) observed with a range of 0.04 to 0.31 h-1. During the maintenance infusions, serum concentrations in the range 1-2 ,ug/ml were usually achieved.
Semilogarithmic plots of serum metoclopramide concentrations vs time following bolus dosage and during therapeutic management of a typical patient in the secondary study are illustrated in Figures 3 and 4 respectively. Tl4ese clearly distinguish the distribution characteristics of metoclopramide; the F ratio tests confirmed that the two compartment model described the data significantly better than the one compartment model (P < 0.05). Table 4 . In particular, dis-study to predict serum levels in this second group tribution half life was 5.1 (± 2.7) min, volume of of patients was assessed by determination of the distribution at steady state was 2.1 (± 0.8) I/kg, difference between predicted and observed clearance was 0.26 (± 0.09) 1 h-1 kg-' and elimi-serum concentrations after 8 h of infusion. The nation half-life was 5.9 (+1.4) h. mean difference was -0.01 + 0.97 (s.d.) p,g/ml Seven patients received high dose metoclo-(n = 7) which indicated no significant bias pramide in the secondary study and the corres-(Student's unpaired t-test). Retrospective anponding serum concentrations achieved during alysis of the infusion data from the secondary the maintenance infusion were in the range study confirmed the wide pharmacokinetic 0.91-1.35 ,ug/ml with the exception of patient variability within this patient group (Table 5) .
HD whose results were markedly different from Clearance ranged from 0.10 to 0.51 1 hIf kg1' and tively were similar to the findings of the pilot investigation (Table 3) . Significant correlations were found between metoclopramide clearance and serum creatinine concentration (r = -0.47, P < 0.05) and between clearance and urea concentration (r = -0.70, P < 0.05). None of the other factors tested showed any significant influence. When clearance was related to urea, and creatinine was subsequently added to the model, no significant improvement in describing the data was obtained since these two indices of renal function were highly correlated with each other (r = 0.67, P < 0.005). These findings indicated that urea, in the range 3-12 mmol/l, was the most useful index of metoclopramide clearance:
In this study, the metoclopramide regimens provided complete prophylaxis against nausea and vomiting in all but two of the 19 patients. The drug was generally well tolerated; in particular no dystonic reactions were observed. One case of diarrhoea was reported but the only common side effect was mild to moderate sedation.
Discussion
A previous study suggested that a two compartment pharmacokinetic model is most appropriate to describe metoclopramide disposition (Bateman et al., 1978) . This observation is supported by results from our secondary study. Several investigations have assessed the pharmacokinetics of conventional doses of metoclopramide in young healthy volunteers (Bateman et al., 1978; Graffner et al., 1979; Ross-Lee et al., 1981) . However, the disposition of this drug in patients with neoplastic disease may be quite different. Such patients tend to be older, cachectic, less active, and are usually receiving other drugs. In addition, perfusion and functional capacity of the liver and kidney may be compromised by the disease. It has been suggested that metoclopramide is a highly extracted drug whose clearance is dependent primarily on liver blood flow. In this study the mean observed clearance was significantly lower than that of normal volunteers (Table 6 ) and this discrepancy may be partly explained by assuming a decreased liver blood flow in the patient group. Similar values were found for the volume of distribution in the central compartment for both patients and volunteers, whereas the volume of distribution at steady state was significantly larger in the patient group. Results indicate that metoclopramide is rapidly distributed in the body; the distribution rate constant appears to be unaltered by advancing age or neoplastic disease. A consistent finding was the significant prolongation of elimination half-life compared to values previously reported for volunteers (Table 6) .
In this study, a detailed examination of the potential dose dependency of metoclopramide disposition was not possible. However, of the five patients given firstly a 50 mg bolus dose and secondly a high dose metoclopramide infusion (together with cyclophosphamide) on separate study days, comparative clearances were identical in one case (HD). In the other four patients, clearances were slightly increased with the higher dosage (Tables 4 and 5) . Further study will be necessary to assess the significance of these results and to exclude a possible pharmacokinetic interaction between metoclopramide and cyclophosphamide.
An important objective of this study was to In this study, high dose metoclopramide was safe and effective; future studies will confirm whether lower infusion regimens are equally appropriate. Pooled results (n = 19) indicated that a loading infusion of 3.61 mg/kg over 15 min followed by a maintenance infusion of 0.36 mg kg-1 h-1 for 10 h should maintain serum levels around 1 ,ug/ml and recent clinical experience has shown this to be satisfactory. This infusion regimen is proposed as a recommendation for the 'average' patient with normal renal and hepatic function. A similar loading and maintenance infusion approach has been proposed recently by Taylor et al. (1984) . The infusion protocol is simple and the resultant serum levels relatively stable. This is in contrast to the original intermittent bolus regimen of Gralla etal. (1981) which causes accumulation, and unnecessary serum level fluctuations of 0.55-2.15 ,ug/ml (minimum after first dose and maximum after fifth dose respectively) in the average patient.
Any patient with a raised serum urea concentration is likely to have a reduced clearance and the maintenance infusion rate should be adjusted according to the predicted individual clearance value. The equation kO =(CT x CL) S can then be utilised to determine the maintenance infusion rate of metoclopramide hydrochloride (k.) where CT is the target serum concentration and S is the salt factor (0.892) for conversion from metoclopramide base. Although the renal route accounts for only 20% of the total clearance in normal individuals, it has been suggested that impaired metabolism and alterations in enterohepatic circulation of metoclopramide may occur in renal failure (Bateman etal., 1981) . The main factors contributing to the interindividual variability in metoclopramide disposition require further evaluation with larger patient numbers, to permit more precise infusion regimens to be recommended for other sub groups of the population.
